Related Experiment Video
Updated: Aug 8, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid
Jessica S Ross1, Jake Lee1, Eduardo Ortiz2
1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background:
Pulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine tumor of the lung. In patients with metastatic disease, systemic therapies typically have low response rates, and long-term survival is poor. PC frequently expresses DLL3, but whether it responds to the DLL3-targeted bispecific T-cell engager tarlatamab is unknown.
Methods:
We analyzed 11 patients with DLL3-high PC treated with tarlatamab at Memorial Sloan Kettering. Tumor response was assessed using RECIST v 1.1.
Results:
Response rate was 8/11 (73%), including one patient with central nervous system-only disease, and disease control rate was 11/11 (100%). All patients experienced reduction of their measurable disease. One patient had progressed at time of data cutoff and median progression-free survival was not reached. Cytokine release syndrome (CRS) occurred in cycle 1 in 9/11 (82%) patients including 2 with grade 3 CRS.
Conclusions:
Tarlatamab demonstrated a high response rate in PC. Cytokine release syndrome was common. Tarlatamab is a promising treatment option for patients with PC.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)